Current Progress in Non-viral RNAi-Based Delivery Strategies to Lymphocytes

Shoshy Mizrahy, Inbal Hazan-Halevy, Niels Dammes, Dalit Landesman-Milo, Dan Peer*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review


RNAi-based therapy holds great promise, as it can be utilized for the treatment of multiple conditions in an accurate manner via sequence-specific manipulation of gene expression. To date, RNAi therapeutics have advanced into clinical trials for liver diseases and solid tumors; however, delivery of RNAi to leukocytes in general and to lymphocytes in particular remains a challenge. Lymphocytes are notoriously hard to transduce with RNAi payloads and are disseminated throughout the body, often located in deep tissues; therefore, developing an efficient systemic delivery system directed to lymphocytes is not a trivial task. Successful manipulation of lymphocyte function with RNAi possesses immense therapeutic potential, as it will enable researchers to resolve lymphocyte-implicated diseases such as inflammation, autoimmunity, transplant rejection, viral infections, and blood cancers. This potential has propelled the development of novel targeted delivery systems relying on the accumulating research knowledge from multiple disciplines, including materials science and engineering, immunology, and genetics. Here, we will discuss the recent progress in non-viral delivery strategies of RNAi payloads to lymphocytes. Special emphasis will be made on the challenges and potential opportunities in manipulating lymphocyte function with RNAi. These approaches might ultimately become a novel therapeutic modality to treat leukocyte-related diseases.

Original languageEnglish
Pages (from-to)1491-1500
Number of pages10
JournalMolecular Therapy
Issue number7
StatePublished - 5 Jul 2017


  • RNAi
  • aptamer
  • drug delivery
  • lipid nanoparticles
  • lymphocytes


Dive into the research topics of 'Current Progress in Non-viral RNAi-Based Delivery Strategies to Lymphocytes'. Together they form a unique fingerprint.

Cite this